Price M R, Sekowski M, Tendler S J
Cancer Research Campaign Laboratories, University of Nottingham, U.K.
J Immunol Methods. 1991 May 17;139(1):83-90. doi: 10.1016/0022-1759(91)90354-i.
Monoclonal antibodies against the protein core of epithelial mucins have been found to react with the immunodominant sequence P D T R P A P (Burchell et al., 1989; Price et al., 1990a). Two immunoadsorbent matrices were prepared by linking the peptide A P D T R P A P G to CNBr-activated Sepharose and by linking the peptide C A P D T R P A P G to activated thiol-Sepharose, so that each immunoadsorbent contained the immunodominant motif. Anti-epithelial mucin antibodies (anti-breast carcinoma antibodies, anti-purified mucin antibodies and anti-human milk fat globule antibodies) were examined for reactivity with these preparations. The initial tests indicated that the substituted CNBr-activated Sepharose displayed lower non-specific antibody binding and this matrix was selected for further investigation. The anti-mucin antibodies were shown to react specifically with this affinity matrix and irrelevant antibodies failed to bind. A Sepharose-peptide immunoadsorbent column was examined for its capacity to purify several of these anti-mucin antibodies and it was determined that this procedure was highly efficient--purified IgG and IgM antibodies could be isolated from either hybridoma tissue culture supernatants or ascitic fluids. The capacity of the column was in excess of 40 mg antibody protein per ml of gel for the IgG3 antibody, C595 (anti-urinary mucin) and at least 10 mg antibody protein per ml of gel for the IgM antibody, NCRC-11 (anti-breast carcinoma). The procedure described permits the efficient purification of anti-mucin antibodies and provides a product which would be suitable for further investigations requiring highly immunoreactive antibodies (e.g., for radioimmunotherapy or immunoscintigraphy in patients with malignant disease).
已发现针对上皮粘蛋白蛋白核心的单克隆抗体可与免疫显性序列P D T R P A P发生反应(Burchell等人,1989年;Price等人,1990年a)。通过将肽A P D T R P A P G连接到溴化氰活化的琼脂糖上以及将肽C A P D T R P A P G连接到活化的巯基琼脂糖上制备了两种免疫吸附基质,这样每种免疫吸附剂都包含免疫显性基序。检测了抗上皮粘蛋白抗体(抗乳腺癌抗体、抗纯化粘蛋白抗体和抗人乳脂肪球抗体)与这些制剂的反应性。初步试验表明,取代的溴化氰活化琼脂糖显示出较低的非特异性抗体结合,因此选择该基质进行进一步研究。结果表明,抗粘蛋白抗体可与这种亲和基质特异性反应,而无关抗体则不结合。检测了一种琼脂糖-肽免疫吸附柱纯化其中几种抗粘蛋白抗体的能力,确定该方法非常有效——可以从杂交瘤组织培养上清液或腹水中分离出纯化的IgG和IgM抗体。对于IgG3抗体C595(抗尿粘蛋白),该柱的容量超过每毫升凝胶40毫克抗体蛋白,对于IgM抗体NCRC-11(抗乳腺癌),至少为每毫升凝胶10毫克抗体蛋白。所述方法可有效纯化抗粘蛋白抗体,并提供一种适合进一步研究的产品,这些研究需要高免疫反应性抗体(例如,用于恶性疾病患者的放射免疫治疗或免疫闪烁成像)。